Cardiology

Baxter Healthcare Corporation has issued a Class II recall of Nexterone (amiodarone HCl), 360 mg/200 mL (1.8 mg/mL), supplied in GALAXY Single-Dose Containers, NDC 43066-360-20. The recall was initiated due to current good manufacturing practice (CGMP) deviations, according to the recall notice. The product is a sterile, nonpyrogenic, iso-osmotic solution in dextrose manufactured in the USA.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

The FDA has classified as a Class II recall Baxter Healthcare Corporation's Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100 mL Single-Dose Container (NDC 0338-9640-12). The recall notice cites cGMP deviations as the reason for the action. No further details on the specific deviation or clinical impact were provided in the source text.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

FDA has classified a recall by Baxter Healthcare Corporation as Class II, affecting Vasopressin in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), supplied as a 100 mL single-dose container (NDC 0338-9647-12). The recall was initiated due to current good manufacturing practice (CGMP) deviations, as reported by FDA.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

The FDA has classified a Class II recall of Baxter Healthcare's Cardene IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL, supplied in GALAXY Single-Dose Containers under NDC 43066-016-10. According to the recall notice, the action was initiated due to current good manufacturing practice (CGMP) deviations. The notice does not specify the nature of the deviations or additional details beyond the product identification and recall classification.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

The American Heart Association has published an updated scientific statement on infective endocarditis, prompted by rising incidence, changing epidemiology, and new diagnostic and treatment options since its 2015 statement. The statement references updated case definitions, non-culture-based pathogen identification, advanced multimodality imaging, a 2019 randomized controlled trial of partial oral antibiotic therapy, and percutaneous mechanical aspiration for select patients with right-sided vegetations. It also notes the growing recognition of multidisciplinary endocarditis teams in managing the condition, and was developed by a multidisciplinary panel of experts in cardiovascular infections.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.